Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 701–800 of 963
Evaluation of Early Dementia (Mild Cognitive Impairment)
Osorio, R. S., Berti, V., Mosconi, L., Li, Y., Glodzik, L., Santi, S. D., & de Leon, M. J. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.003 · Cited by 5
14 Amyloid Imaging and (What is “Normal”?) Aging
Klunk, W. E., & Mathis, C. A. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0014 · Cited by 5
Self-citationSasaki, K., Maikusa, N., Imabayashi, E., Yuasa, T., & Matsuda, H. (2016) · Brain and Behavior · doi:10.1002/brb3.532 · Cited by 5
“…with the existing diagnostic methods (Braak & Braak, 1991; Drzezga et al., 2008; Dubois et al., 2010; Förster et al., 2012; Hirata et al., 2005; Ikonomovic et al., 2008; Klunk et al., 2004; Lowe et al., 2009; Ma et al., 2014; Mikhno et al., 2008; Price et al., 2005; Rabinovici et al., 2008;…”
MethodNeuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
Reply: Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden
Gomperts, S. N., Johnson, K. A., & Growdon, J. H. (2013) · Movement Disorders · doi:10.1002/mds.25309 · Cited by 5
Alegro, M., Chen, Y., Ovando, D., Heinser, H., Eser, R., Ushizima, D., Tosun, D., & Grinberg, L. T. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/698902 · Cited by 6
Wood, J. I., Dulewicz, M., Ge, J., Stringer, K. M., Szadziewska, A., Desai, S., Koutarapu, S., Hajar, H. B., Blennow, K., Zetterberg, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.08.617019 · Cited by 5
Predicting biological age using an accumulated neurotoxicity biomarker for amyloid beta oligomers
Kuznetsov, A. V. (2026) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqag005 · Cited by 4
Imaging biomarkers for amyloid: a new generation of probes and what lies ahead
Leuzy, A., Zimmer, E. R., Bhat, V., Rosa‐Neto, P., & Gauthier, S. G. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000118 · Cited by 4
Yamakuni, R., Murakami, T., Ukon, N., Kakamu, T., Toda, W., Hattori, K., Sekino, H., Ishii, S., Fukushima, K., Matsuda, H., et al. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01955-z · Cited by 5
“In vivo Aβ deposition analysis methods include Aβ positron-emission tomography (PET) [6], cerebrospinal Extended author information available on the last page of the article fluid (CSF) Aβ levels [7, 8], and plasma Aβ biomarkers [9].”
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Biomathematical screening of amyloid radiotracers with clinical usefulness index
Nai, Y., Shidahara, M., Seki, C., & Watabe, H. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.006 · Cited by 6
PET and SPECT Imaging of Neurodegenerative Diseases
Drzezga, A. E., Bischof, G. N., Giehl, K., & van Eimeren, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00085-5 · Cited by 4
Newberg, A. B., Coble, R., Khosravi, M., & Alavi, A. A. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.009 · Cited by 4
Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice
Oh, S. J., Lee, N., Nam, K. R., Kang, K. J., Han, S. J., Lee, K. C., Lee, Y. J., & Choi, J. Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.930613 · Cited by 4
“In clinical studies, growing evidence suggests that amyloid PET correlates with the pathology of AD (Ikonomovic et al., 2008; Sojkova et al., 2011).”
BackgroundNeuropathological Basis of Alzheimer’s Disease and Alzheimer’s Disease Diagnosis
Schneider, J. A., Montine, T. J., Sperling, R. A., & Bennett, D. A. (2012) · Advances in biological psychiatry · doi:10.1159/000335384 · Cited by 8
Advances in structural and molecular neuroimaging in Alzheimer's disease
Ellis, K. A., Rowe, C. C., Szoeke, C. E. I., Villemagne, V. L., Ames, D. J., Chételat, G., Martins, R. N., Masters, C. L., Fripp, J., Acosta, O., et al. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb02938.x · Cited by 5
Diagnostic précoce de la maladie d’Alzheimer
Saint‐Aubert, L., Puel, M., Chollet, F., & Pariente, J. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.006 · Cited by 6
Amyloid Imaging in Dementia and Neurodegenerative Disease
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_11 · Cited by 4
Kim, S., Yoon, D., Seong, J., Jeong, Y. J., Kang, D., & Park, K. W. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050547 · Cited by 3
“Some studies have shown high safety and accuracy for identifying amyloid plaques in the brain compared with 11C-PiB PET [16].”
BackgroundAmyloid imaging with PET: methodological issues and correlative studies
Lucignani, G. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1124-y · Cited by 3
“which this tracer binds to different types of Aβ plaques and τ-NFTs, Ikonomovic et al., of the Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, USA [ 4 ], examined 28 clinically diagnosed and autopsy-confirmed AD subjects, including one who had undergone 11 C-PiB-PET imaging 10 months…”
Iskra, I., Visvikis, D., Koole, M. J. B., Armstrong, I. S., Vanhove, C., Žagar, I., Middlebrooks, T., Bormans, G. M., Cleeren, F., Weehaeghe, D. V., et al. (2021) · doi:10.52717/pwze5872 · Cited by 3
Apostolova, L. G., DeKosky, S. T., & Cummings, J. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00091-8 · Cited by 4
Self-citationGreer, O., Cheng, R., Tamres, L. K., Mattos, M. K., Morris, J. L., Knox, M. L., & Lingler, J. H. (2023) · Geriatric Nursing · doi:10.1016/j.gerinurse.2023.07.007 · Cited by 3
Clinical and Pathological Validation of CT-Based Regional Harmonization Methods of Amyloid PET
Kim, S.-J., Jang, H., Yoo, H., Na, D. L., Ham, H., Kim, H. J., Kim, J. P., Farrar, G., Moon, S. H., & Seo, S. W. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004937 · Cited by 3
Mueller, K. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-45190-4_4 · Cited by 5
Vemuri, P., & Murray, M. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00070-4 · Cited by 3
Niknam, N., Khaefi, S., Heidarpour, H., Sadeghi, M., Jafari, N. A., Mohammadi, S., Ahmadi, Z. S., Ahangar‐Sirous, R., Mayeli, M., & Seyedmirzaei, H. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111141 · Cited by 3
Synthesis optimization of pittsburgh compound B by the captive solvent method
Clemente, G. S., Alves, V., & Abrunhosa, A. (2012) · IEEE Portuguese Meeting on Bioengineering · doi:10.1109/enbeng.2012.6331358 · Cited by 4
Symptomatic and preclinical Alzheimer’s disease: Neuropathology and imaging
Thal, D. R. (2016) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2016.01.001 · Cited by 3
Challenges in Production of Alzheimer’s Tracer C-11 PiB
Ruangma, A., Panpitpat, S., Saonam, T., Kijprayoon, S., Ngokpol, S., Tanasirimanon, M., Khajitkhajonwong, S., Tuamputsa, S., Rachadara, S., & Chinvarun, Y. (2015) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2015.02.015 · Cited by 3
Neuropathology of HIV-1 Disease
Soontornniyomkij, V. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7290-6_8 · Cited by 4
Prion-Like Propagation in Neurodegenerative Diseases
Peelaerts, W., Baekelandt, V., & Brundin, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00008-0 · Cited by 4
Osama, A., Khalil, T. H., Negm, M., El-Razek, R. A., & Abouelhamd, H. (2020) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-020-00232-w · Cited by 3
Takita, H., Doishita, S., Yoneda, T., Tatekawa, H., Abe, T., Itoh, Y., Horiuchi, D., Tsukamoto, T., Shimono, T., & Miki, Y. (2022) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2021-0123 · Cited by 3
Vemuri, P., Jack, C. R., & Murray, M. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00014-3 · Cited by 3
Coffee: Health effects and various disease treatments
Vo, T. S., Vo, T. T. B. C., & Vo, T. T. T. N. (2022) · Food and Health · doi:10.3153/fh22032 · Cited by 3
The specificity of amyloid imaging in the diagnosis of neurodegenerative diseases
Frisoni, G. B., & Giannakopoulos, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.007 · Cited by 3
Can amyloid PET differentiate “pure” LBD from AD with or without LBD copathology?
Landau, S. M., & Villemagne, V. L. (2019) · Neurology · doi:10.1212/wnl.0000000000008812 · Cited by 3
“Second, diffuse plaques (and not neuritic plaques) were the primary contributor to the PiB-PET cortical signal, an unexpected finding given previous observations that PiB binding is likely to be weaker for diffuse compared with neuritic plaques.(8)”
ResultWhere Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?
Sánchez‐Soblechero, A., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Irure, J., López‐Hoyos, M., Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Cuenca-Vera, O., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230678 · Cited by 2
“While CSF biomarkers values correlate with pathological changes in AD [7–10], amyloid PET imaging allows visualization of fibrillar amyloid plaques [11–13].”
Koay, H., Haskali, M. B., Zuylekom, J. V., Cullinane, C. M., McLean, C., White, J. M., Roselt, P. D., & Donnelly, P. S. (2025) · Dalton Transactions · doi:10.1039/d5dt00621j · Cited by 2
Zhao, K., Xie, H., Fonzo, G. A., Carlisle, N. B., Jacobs, T., Osorio, R. S., Church, A., Lin, F. V., Zhang, Y., & the ADNI Study Group (2026) · Science Advances · doi:10.1101/2025.07.20.665707 · Cited by 2
Mulligan, M., Beiser, A., O’Donnell, A., Banerjee, A., Ghosh, S., Thibault, E. G., Fakhri, G. E., Johnson, K. A., Seshadri, S. S., & McGrath, E. R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251372561 · Cited by 2
Neuropathology and Biomarker Correlates of Late Onset Alzheimer’s Disease in Aged Old World Monkeys
Zeiss, C. J., Duque, A., & Huttner, A. J. (2025) · Toxicologic Pathology · doi:10.1177/01926233251388069 · Cited by 2
“65 This level of PiB uptake is associated with future cognitive decline.”
Dynamic Complexity and Causality Analysis of Scalp EEG for Detection of Cognitive Deficits
McBride, J. C. (2014) · Cited by 4
Fandos, N., Pascual‐Lucas, M., Sarasa, L., Terencio, J. V., Sáez, M. E., Tartari, J. P., Sanabria, Á., Sotolongo‐Grau, Ó., Cano, A. C., Tárraga, L., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100465 · Cited by 2
“The diagnosis of AD has been primarily based on cerebrospinal fluid (CSF) biomarkers, such as A β 42 [10], total tau (t-tau) and phosphorylated tau (p-tau) [11], or neuroimaging techniques like positron emission tomography (PET), to assess amyloid pathology [12].”
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Nishida, H., Hayashi, Y., Harada, N., Sakurai, T., & Wakida, K. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8534-16 · Cited by 2
“Amyloid positron emission tomography (PET) allows for the in vivo visualization of amyloid beta (Aβ) peptide accumulation, which is an important biomarker and a useful tool for the diagnosis of AD (8-10).”
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Developing Low Molecular Weight PET and SPECT Imaging Agents
Xue, L., Jie, C. V. M. L., Desrayaud, S., & Auberson, Y. P. (2024) · ChemMedChem · doi:10.1002/cmdc.202400094 · Cited by 2
Wu, X., Shirani, H., Vidal, R., Ghetti, B. F., Ingelsson, M., Klingstedt, T., & Nilsson, K. P. R. (2024) · ChemistryOpen · doi:10.1002/open.202400186 · Cited by 4
Joshi, N. V., Páez, X., & Araque, H. (2012) · Medical Acupuncture · doi:10.1089/acu.2012.0873 · Cited by 2
“18,19 The latter technique has been widely employed over the past few years, as it provides a wealth of information related to amyloid deposition in vivo.”
InfluentialBonavita, V., Caltagirone, C., Mariani, C. B., Padovani, A., Scarpini, E. A., & Sorbi, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129000 · Cited by 2
PET Tracers for Beta-Amyloid and Other Proteinopathies
Nordberg, A. K. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_8 · Cited by 2
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 3
Kepe, V. (2013) · PET Clinics · doi:10.1016/j.cpet.2013.08.002 · Cited by 2
Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
Leuzy, A., Zimmer, E. R., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Translational Neuroscience · doi:10.2478/s13380-014-0205-y · Cited by 2
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Clinical Meaningfulness of Biomarker Endpoints in Alzheimer’s Disease Research
Ng, K. P., Pascoal, T. A., Li, X., Rosa‐Neto, P., & Gauthier, S. G. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_16 · Cited by 2
Positron Emission Tomography (PET) Imaging
Ponto, L. L. B. (2018) · Wiley eBooks · doi:10.1002/9781118772034.ch9 · Cited by 2
Bombois, S. (2018) · Médecine Nucléaire · doi:10.1016/j.mednuc.2018.03.131 · Cited by 3
Groot, C., Tolboom, N., Ikonomović, M. D., Lammertsma, A. A., Boon, B. D. C., Barkhof, F., Scheltens, P., Klunk, W. E., Rozemüller, A. J. M., Ossenkoppele, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180316 · Cited by 2
Self-citationDetection and Analysis of Human Brain Disorders
Tiwari, D., & Jha, H. C. (2018) · Advances in intelligent systems and computing · doi:10.1007/978-981-13-0923-6_61 · Cited by 2
Hatashita, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00019-7 · Cited by 2
Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images
Seiffert, A. P., Gómez‐Grande, A., Milara, E., Velasco, S. L., Villarejo‐Galende, A., Aguilera, E. J. G., & González, P. S. (2021) · Applied Sciences · doi:10.3390/app11051991 · Cited by 2
“Positron emission tomography (PET) imaging with Aβ-binding tracers, like [11C]Pittsburgh compound-B (PiB) [3], [18F]florbetapir (FBP) [4], [18F]florbetaben (FBB) [5] and [18F]flutemetamol (FMM) [6], allow for the in-vivo evaluation of its deposition in the brain.”
BackgroundAlzheimer's neuropathology in Down syndrome: From gestation to old age
Mufson, E. J., Miguel, J. C., & Perez, S. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00011-6 · Cited by 3
Ni, R. (2015) · Figshare · Cited by 2
[ 18 F]-Florbetapir PET: Towards Predicting Dementia in Adults with Down SyndromePreprint
Keator, D. B., Doran, E. W., van Erp, T. G. M., Phelan, M. J., Tseung, K., Yassa, M. A., Potkin, S. G., & Lott, I. T. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/235440 · Cited by 5
Perani, D. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.8343973.8791070 · Cited by 2
Mpambani, F. (2013) · theses.fr (ABES) · doi:10.70675/82ac4709z7b0bz470az97a4zd47f0f82a7e2 · Cited by 3
Cortical thickness computation by solving tetrahedron-based harmonic field
Kong, D., Fan, Y., Hao, J., Zhang, X., Su, Q., Yao, T., Zhang, C., Xiao, L., & Wang, G. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103727 · Cited by 1
Biomarkers for Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Imaging
Bozzali, M., & Serra, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_12 · Cited by 1
Update Amyloid-Bildgebung in der Diagnostik der Neurodegeneration
Drzezga, A. E., & Giehl, K. (2022) · Angewandte Nuklearmedizin · doi:10.1055/a-1712-6110 · Cited by 1
Clinical Applications of PET-MRI Technique in Alzheimer’s Disease
Chen, L. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v45i.7306 · Cited by 1
Strużek, K., Karamus, K., Rejmak, R. W., Borowska-Łygan, M., Urban, W., Tomaszewski, J., Gryc, A., Lipiec, J., & Grudzień, M. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.60238 · Cited by 1
Mulligan, M. D., Scott, M. R., Yang, Q., Wang, R., Ghosh, S., Johnson, K. A., Beiser, A., Seshadri, S. S., & McGrath, E. R. (2026) · Neurology Open Access · doi:10.1212/wn9.0000000000000057 · Cited by 1
Amyloid Imaging PET Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation
Svedberg, M. M., Hellström‐Lindahl, E., Rahman, O., & Hall, H. (2012) · InTech eBooks · doi:10.5772/31813 · Cited by 1
“…have reported correlations between in vivo [11C]PIB retention and with region-matched postmortem quantification of [3H]PIB binding, Aβ plaque loads and Aβ peptide levels but not with neurofibrillar tangles (Bacskai et al., 2007; Ikonomovic et al., 2008; Kadir et al., 2011; Rosen et al., 2011).”
BackgroundMethodInfluentialAshraf, A., Mehta, P. D., & Edison, P. (2012) · Reviews in Clinical Gerontology · doi:10.1017/s0959259812000160 · Cited by 1
Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics
Yuen, E., Liu, E., & Kinney, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_14 · Cited by 1
Seiffert, A. P., Gómez‐Grande, A., González, P. S., Dghoughi, W., Villarejo‐Galende, A., Bueno, H., & Aguilera, E. J. G. (2019) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-31635-8_52 · Cited by 1
Alzheimer-Associated Pathology in the Extracellular Space
Braak, H., & Tredici, K. D. (2014) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-12679-1_8 · Cited by 1
Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings
Ossenkoppele, R., Booij, J., Scheltens, P., & van Berckel, B. N. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_9 · Cited by 1
Möglichkeiten moderner Bildgebungstechnologien im Rahmen der Frühdiagnostik von Alzheimererkrankung
Unschuld, P. G. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000674 · Cited by 1
Jahng, G., Xu, S., & Kim, M. (2012) · Medical Physics · doi:10.1118/1.4754655 · Cited by 1
Vlaslaer, A. V., Mortishire‐Smith, R. J., Mackie, C. E., Langlois, X., & Schmidt, M. E. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-10 · Cited by 1
“Retention of (11)C-PiB in the cortex correlates with the distribution of insoluble deposits of Aβ [1] and has been investigated extensively as a biomarker for Alzheimer’s disease (AD) [2] and used as an endpoint in interventional trials [3,4].”
BackgroundUtilidad de la neuroimagen amiloidea en Neurología asistencial
Méndez, P. C., Cohen, G., Russo, M. J., Suarez, M. F., Nahas, F., Russo, G., Claudio, W., Paz, S., Leonardo, T., Campos, J., et al. (2014) · Neurología Argentina · doi:10.1016/j.neuarg.2014.02.003 · Cited by 2
Advances in Alzheimer’s Disease Management
Gauthier, S. G., & Rosa‐Neto, P. (2012) · doi:10.2217/9781780840840 · Cited by 1
Amyloid Imaging in Dementia and Related Disorders
Camacho, V., & Carrió, I. (2016) · Springer eBooks · doi:10.1007/978-3-319-31614-7_7 · Cited by 1
Neuroimaging Advances in Alzheimer's Disease
Schonhaut, D. R., & Rabinovici, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00017-2 · Cited by 4
Negative 11C-PIB PET Predicts Lack of Alzheimer’s Disease Pathology in Postmortem Examination
Scheinin, N. M., Gardberg, M., Röyttä, M., & Rinne, J. O. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170569 · Cited by 1
Սիմոնյան, Կ. Վ., Galstyan, H. M., & Chavushyan, V. A. (2019) · Neurophysiology · doi:10.1007/s11062-020-09827-8 · Cited by 2
“This pathology is characterized by deposition of insoluble aggregates of fibrillary amyloid β (Aβ) protein in neuritic plaques and blood vessels (cerebral amyloid angiopathy) and accumulations of tau protein in neurofibrillary tangles [1].”
BackgroundLamar, M., Wortzel, H. S., Libon, D. J., Wambach, D. M., Price, C. C., & Kumar, A. A. (2012) · Wiley eBooks · doi:10.1002/9781119968900.ch4 · Cited by 1
Neurodegenerative and movement disorders
(2012) · CRC Press eBooks · doi:10.1201/b13258-14 · Cited by 1
Cognitive Aging and the Transition to Early Alzheimer’s Disease
Mormino, E. C., & Jagust, W. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190917982.013.59 · Cited by 1
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Cheng, Y., He, Y., Gopinath, K. K., Billot, B., Iglesias, J. E., Wu, C., Dodge, H. H., Wills, A.-M. A., Carlyle, B. C., Kivisäkk, P., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf210 · Cited by 2
“While PET imaging can reveal both total and regional insoluble, fibrillar amyloid and tau accumulation, 13 less is known about how CSF Alzheimer’s disease biomarkers, 3,14,15 which reflect net production and clearance rates of soluble amyloid and tau species, relate to brain atrophy.”
Chen, J., Xie, C., Wu, R., Zhang, D., Wen, F., Nie, H., Xue, L., Zha, Z., & Wang, J. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112037 · Cited by 1
In Vivo Imaging in Neurodegenerative Diseases
Wang, X., Arbel‐Ornath, M., Wegmann, S., Kastanenka, K. V., & Bacskai, B. J. (2014) · Springer eBooks · doi:10.1007/978-94-017-9361-2_3 · Cited by 1
Posteriore kortikale Atrophie – ein heterogenes Syndrom: Eine Fallserie
Conrad, J., Kremmyda, O., Högen, T., Brendel, M., Rominger, A., Levin, J., & Danek, A. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0697-3 · Cited by 1
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies
Dubois, B., Villain, N., Jacova, C., & Uspenskaya, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_13 · Cited by 1
Leighty, R. E. (2009) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.